Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

OBJECTIVE: This study aimed to evaluate the safety and tolerability of OP-724, a CREB-binding protein/β-catenin inhibitor, in patients with advanced primary biliary cholangitis (PBC). DESIGN: An open-label, non-randomised, phase 1 trial was conducted at two hospitals in Japan. Patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Masamichi, Ogawa, Eiichi, Harada, Kenichi, Imamura, Jun, Saio, Masanao, Ikura, Yoshihiro, Yatsuhashi, Hiroshi, Murata, Kazumoto, Miura, Kouichi, Ieiri, Ichiro, Tanaka, Atsushi, Kimura, Kiminori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710334/
https://www.ncbi.nlm.nih.gov/pubmed/36442892
http://dx.doi.org/10.1136/bmjgast-2022-001001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710334/
https://www.ncbi.nlm.nih.gov/pubmed/36442892
http://dx.doi.org/10.1136/bmjgast-2022-001001

Ejemplares similares